Hangzhou Tigermed Consulting Co., Ltd (HNGZY)
OTCMKTS
· Delayed Price · Currency is USD
4.000
0.00 (0.00%)
Jun 25, 2025, 8:00 PM EDT
HNGZY Revenue
Hangzhou Tigermed Consulting had revenue of 1.56B CNY in the quarter ending March 31, 2025, a decrease of -5.79%. This brings the company's revenue in the last twelve months to 6.51B, down -10.12% year-over-year. In the year 2024, Hangzhou Tigermed Consulting had annual revenue of 6.60B, down -10.58%.
Revenue (ttm)
6.51B CNY
Revenue Growth
-10.12%
P/S Ratio
6.37
Revenue / Employee
638.89K CNY
Employees
10,185
Market Cap
5.71B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.60B | -780.92M | -10.58% |
| Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
| Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
| Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
| Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Hangzhou Tigermed Consulting News
- 10 months ago - Hangzhou Tigermed Consulting reports Q2 results - Seeking Alpha